Unigen announces the publication of a rapid-relief clinical study on Univestin®, its proprietary joint health ingredient. This publication marks the 13th human clinical study to be published on Univestin and extends the claim substantiation to working in as quickly as three days for joint stiffness. The study also showed rapid benefits to joint comfort and function. This latest study builds on prior clinical studies which had established Univestin’s effectiveness for joint health over longer periods of supplementation. The study was published in the Journal of Medicinal Food and was conducted at Florida State University by Dr. Arjmandi and his team of researchers.
When asked about the impact of this study, Unigen’s chief business officer, Thomas Niederkorn, Ph.D. said, “The expansion of Univestin’s claims to include rapid relief confirms what we had already been hearing through our commercial partners. Univestin works quickly and effectively at reducing stiffness and discomfort while improving mobility. This is another example of the continuing clinical support we provide to our commercial partners as we strive to provide efficacious and safe ingredients that will have a meaningful impact on people’s lives.”
Unigen’s commitment to its partners’ success is evident in its continued study of its proprietary ingredients, with a focus on providing additional clinical and new claim support.